Maravai LifeSciences subsidiaries Cygnus Technologies and TriLink BioTechnologies have jointly introduced the AccuRes Host Cell DNA Quantification Kits, designed to enhance the safety and stability of biotherapeutics.
 
The new kits leverage cutting-edge technologies to provide unparalleled sensitivity and specificity in detecting residual host cell DNA, a critical factor in ensuring regulatory compliance. AccuRes utilizes probe-based quantification, ensuring accurate targeting of the specific host cell line. The kits are compatible with various real-time PCR instruments, offering flexibility and cost-effectiveness.
 
“This collaboration between Cygnus and TriLink has allowed us to bring decades of experience and advanced technology to the development of AccuRes,” said Alla Zilberman, VP of Technical Marketing and Business Development at Cygnus. “With these novel host cell DNA quantification kits, our customers will be able to utilize Cygnus for all their host cell protein and host cell DNA analysis needs.”
 
The AccuRes kits feature Cygnus’ proprietary extraction method and TriLink’s patented CleanAmp dNTPs and Hot Start Taq DNA Polymerase. This combination delivers exceptional sensitivity and accuracy, enabling precise monitoring of host cell DNA levels throughout the biotherapeutic manufacturing process.
 
“As the industry continues to innovate and develop more complex biotherapeutics, it’s critical we have the capabilities to ensure these drug substances are safe and stable,” shared Justin Barbosa, VP and General Manager of TriLink Discovery. “Our CleanAmp dNTPs improve sensitivity, specificity, and prevent mis-priming—it’s a great addition to any assay. We’re grateful for the collaboration with Cygnus and look forward to future opportunities.”